GSK said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in ...

Inhalers used to treat symptoms of respiratory disease can be potent sources of greenhouse gases. Drugmakers are planning to ...

U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...

U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...

The drugmaker has cut costs already and has no coming product approvals or research that could offer a quick lift.

While recent CDC guidance threatens to shrink the market for a new class of immunizations, GSK continues to build the case ...

GSK presents positive data for AREXVY, its respiratory syncytial virus (RSV) vaccine, indicating protection over three RSV ...

GSK (GSK) announces that its Arexvy vaccine shows promise in protecting adults aged 60+ against RSV over three seasons in a ...

Cumulatively, data showed the shot to be 63% effective across the three-year period. However, efficacy appeared to wane and GSK said it expects revaccination will eventually be needed.

GSK plc (GSK, GSK.L) announced Tuesday new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial evaluating ...

WeightWatchers said on Tuesday it is adding a compounded version of Novo Nordisk's obesity drug Wegovy to its ...

The UK High Court has ruled that two GSK respiratory syncytial virus (RSV) vaccine patents are invalid in an action involving ...